Status: Recruiting
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Eric Stephen Winer, MDUpdated: Jul 18, 2025Locations: 1
Eligibility criteria
Age 18 and older [+16]
Subjects who have known Acute Promyelocytic Leukemia. [+17]